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Introduction {#sec1}
============

Major histocompatibility complex class I (MHC I) molecules are transmembrane proteins that present fragments of the cellular proteome, in the form of short peptides, on the cell surface for inspection by cytotoxic T lymphocytes (CTLs). The MHC I locus contains the most polymorphic genes within humans, comprising over 10,000 different alleles. The vast majority of the polymorphisms in MHC I reside at the sites of the peptide binding groove that determine peptide specificity. Consequently, different MHC I molecules bind distinct sets of peptides and are, thus, capable of eliciting highly specific CD8^+^ T cell responses. The peptide repertoire displayed by individual MHC I molecules has a critical influence on an individual's susceptibility to infectious diseases. For instance, specific pairs of MHC I molecules, such as HLA-B^∗^35:01 and B^∗^35:03, HLA-B^∗^42:01 and B^∗^42:02, and HLA-B^∗^57:03 and B^∗^57:02, that differ in only one amino acid are associated with different progression rates of HIV, mainly due to the different peptide repertoires presented ([@bib7], [@bib15], [@bib16]). Furthermore, although the inheritance of specific human leukocyte antigen (HLA) alleles, such as HLA-B^∗^27:05 and HLA-B^∗^51, is linked to certain autoinflammatory diseases ([@bib5], [@bib22]), the role of these MHC I molecules in disease pathogenesis has yet to be fully elucidated. Thus, in-depth understanding regarding how polymorphisms in MHC I affect peptide selection, molecular stability, and their interactions with molecular chaperones is vital for understanding the role that variation in MHC I has on disease susceptibility.

Two molecular chaperones, tapasin and TAPBPR, play an important role in influencing the peptide repertoire presented on MHC I molecules to the immune system. Tapasin, the first discovered peptide editor for MHC I, works within the confines of the peptide-loading complex (PLC), which is the site where peptides are translocated from the cytoplasm into the endoplasmic reticulum ([@bib23], [@bib28]). Tapasin is responsible for loading peptide-receptive MHC I molecules with high-affinity peptides, by sequentially exchanging lower affinity peptides for higher affinity peptides ([@bib3], [@bib10], [@bib33], [@bib34]). Recent evidence suggests that TAPBPR functions as a second editor on the pathway, which, unlike tapasin, performs peptide exchange outside of the PLC ([@bib2], [@bib8], [@bib9], [@bib18]). Current data support a role for TAPBPR in refining the peptide repertoire displayed on MHC I ([@bib9], [@bib11], [@bib20]). Moreover, TAPBPR was shown to be capable of recruiting UDP-glucose:glycoprotein glucosyltransferase 1 (UGT1) to reglucosylate MHC I and, consequently, recycle it to the PLC ([@bib20]).

Although tapasin's ability to interact with and edit peptides on a wide variety of different HLA molecules, albeit mainly HLA-B allotypes ([@bib27], [@bib34], [@bib25]), has been extensively investigated for over 20 years, knowledge regarding which HLA molecules TAPBPR is capable of performing peptide editing on is in its infancy by comparison ([@bib9], [@bib11], [@bib12], [@bib18]). Our recent work identifying a functional role of the TAPBPR K22-D35 loop in mediating peptide selection suggests that TAPBPR may have a prominent effect on some but not all MHC I molecules ([@bib11]). Furthermore, variations in MHC I appear to influence the molecular mechanism by which TAPBPR shapes the peptide repertoire on MHC I ([@bib11]). Thus, it is now crucial to understand on which HLA I molecules TAPBPR is able to function as a peptide editor.

Here, by comparing the ability of TAPBPR to bind to a panel of 97 different HLA I molecules, using LABScreen single antigen HLA class I beads (SABs), with further validation using cell-based assays, we reveal a striking preference of TAPBPR for HLA-A allotypes over HLA-B and -C and particularly for the members of the HLA-A2 and -A24 superfamilies. Furthermore, we identify that specific residues of the peptide-binding groove influence the propensity of MHC I to undergo TAPBPR-mediated peptide editing. This work reveals that MHC I polymorphisms strongly influence both chaperone association and, consequently, the level of peptide editing exerted on MHC I molecules.

Results {#sec2}
=======

HLA-A Molecules Exhibit Stronger Binding to TAPBPR Compared to HLA-B and -C Molecules {#sec2.1}
-------------------------------------------------------------------------------------

Although TAPBPR naturally functions on MHC I intracellularly, when given access to the plasma membrane, TAPBPR can bind to and exchange peptides on surface-expressed MHC I molecules ([@bib12]). Thus far, we have only tested the ability of TAPBPR to bind to surface-expressed HLA-A2, HLA-A68, and H-2K^b^ ([@bib11], [@bib12]). Here, we sought to perform a comprehensive study of human TAPBPR binding to the products of different HLA I alleles in an unbiased manner. We compared the ability of soluble TAPBPR to bind to 97 different HLA I allotypes that are prevalent across different human subpopulations around the world by using SABs ([@bib26]). The HLA I molecules coupled to these beads were produced and purified from Epstein Barr virus (EBV)-transformed cell lines and should, thus, be representative of the MHC I pool found in a cell, loaded with a wide range of peptides. Although, SABs are mainly used clinically to assess pre-transplant risks of allograft rejection ([@bib35]), they have also provided insight into MHC I molecules:immune receptor interactions ([@bib14]).

Here, SABs were treated with 1 μM soluble TAPBPR, and the levels of TAPBPR bound to each individual bead-coupled HLA I molecule were assessed using flow cytometry ([Figure 1](#fig1){ref-type="fig"}A). The screen revealed a striking preference of TAPBPR for HLA-A molecules over both HLA-B and -C allotypes ([Figure 1](#fig1){ref-type="fig"}B; [Figure S1](#mmc1){ref-type="supplementary-material"}). Among all 97 allotypes screened, the top 11 strongest TAPBPR binders belong to the HLA-A group ([Figure 1](#fig1){ref-type="fig"}B). In addition, the top 4 strongest HLA-A binders, namely HLA-A^∗^68:02, A^∗^23:01, A^∗^69:01, and A^∗^02:01, all display \>8-fold higher TAPBPR binding levels than the strongest binders among the HLA-B and -C groups, namely HLA-B^∗^73:01 and HLA-C^∗^01:02, respectively. In fact, the majority of HLA-B and -C allotypes on the SABs did not show significant binding to TAPBPR ([Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B). The staining of the SABs with W6/32 antibody revealed similar levels of peptide-loaded MHC I molecules across the HLA I library ([Table S1](#mmc1){ref-type="supplementary-material"}). Moreover, the recombinant TN5 mutant of TAPBPR, which is unable to associate with MHC I ([@bib8]), showed no binding to the SABs ([Figure S1](#mmc1){ref-type="supplementary-material"}D), demonstrating that TAPBPR does not associate non-specifically to the SABs.Figure 1HLA-A Molecules, Particularly Members of the A2 and A24 Supertypes, Exhibit Stronger Binding to TAPBPR Than HLA-B and -C Molecules(A) Schematic representation of the LABScreen SAB assay used to measure soluble TAPBPR binding to individual HLA I allotypes. The SABs were incubated with 1 μM TAPBPR or with 100 nM TAPBPR ([Figure S1](#mmc1){ref-type="supplementary-material"}C) for 1 h, at 22°C, and then stained for TAPBPR.(B) Bar graph showing the level of TAPBPR binding to the top 34 binders of the HLA I library, comprising HLA-A (blue), HLA-B (orange), and HLA-C (red) molecules.(C) Bar graph summarizing TAPBPR binding to all HLA-A allotypes tested, with members of the HLA-A2 (blue) and -A24 (green) supertypes highlighted. TAPBPR binding to all HLA-B and -C allotypes tested is shown in [Figures S1](#mmc1){ref-type="supplementary-material"}A and S1B, respectively.Error bars show mean fluorescence intensity (MFI) ± SD from triplicates within one experiment. This experiment is representative of three independent experiments.

HLA-A2 and -A24 Superfamily Members Are the Strongest TAPBPR Binders {#sec2.2}
--------------------------------------------------------------------

Despite TAPBPR showing a clear preference for HLA-A over -B and -C allotypes, there were numerous HLA-A molecules on the SABs that did not show significant binding to TAPBPR, such as HLA-A^∗^01:01, A^∗^11:01, A^∗^36:01, A^∗^26:01, or A^∗^68:01 ([Figure 1](#fig1){ref-type="fig"}C). Interestingly, the top eight strongest TAPBPR binders, namely A^∗^68:02, A^∗^23:01, A^∗^69:01, A^∗^02:01, A^∗^24:02, A^∗^02:03, A^∗^24:03, and A^∗^02:06, are all members of the HLA-A2 and -A24 superfamilies, according to previous classifications ([@bib29]), whereas the low binders are exclusively members of the HLA-A1 and -A3 supertypes. This classification of HLA I into supertypes was based on overlapping peptide repertoires, chemical specificity of both B and F pockets, and on the amino acid sequence similarity around the two pocket regions ([@bib29]).

HLA I Molecules Show a Similar TAPBPR-Binding Hierarchy in a Cellular System {#sec2.3}
----------------------------------------------------------------------------

Due to the limited information available regarding the precise composition of the HLA I molecules in the SABs, it was important to validate the results obtained from the SABs by using cellular systems. Recently, we have developed two cell-based assays to assess TAPBPR binding, as well as TAPBPR-mediated peptide exchange, on surface-expressed MHC I molecules ([@bib12]). To test the ability of soluble TAPBPR to bind to different HLA I molecules expressed on cells, we first reconstituted HeLaM cells, in which HLA-A, -B, and -C heavy chains had been knocked out using CRISPR (HeLaM-HLA-ABC^KO^)([@bib19]), with a panel of 27 individual HLA I allotypes that spanned the entire TAPBPR binding hierarchy ([Figure 1](#fig1){ref-type="fig"}). Flow cytometry using the monoclonal antibody (mAb) W6/32 showed similar surface expression levels for all 27 HLA I allotypes except HLA-C^∗^02:02 ([Figure 2](#fig2){ref-type="fig"}A; [Figure S2](#mmc1){ref-type="supplementary-material"}A).Figure 2MHC I Molecules Show a Similar TAPBPR Binding Hierarchy in a Cellular System(A) Bar graphs show surface expression levels of each HLA I allotype upon reconstitution in HeLaM-HLA-ABC^KO^ cells.(B) Histograms depict levels of soluble TAPBPR bound to each HLA I allotype present at the cell surface, after cells were incubated with 1 μM TAPBPR for 30 min at 37°C; HLA I allotypes were grouped into either strong (blue) or weak (red) TAPBPR binders. HLA I-deficient cells were shown in gray.(C) Bar graph summarizing TAPBPR binding measured as in (B).Error bars show MFI ± SD from three independent experiments.

We next assessed the ability of recombinant TAPBPR to bind to the surface of each cell line from the HeLaM HLA panel ([Figures 2](#fig2){ref-type="fig"}B and 2C). We observed no TAPBPR binding to HeLaM-HLA-ABC^KO^ cells ([Figure 2](#fig2){ref-type="fig"}B), as previously shown ([@bib12]). The results showed a similar hierarchy of TAPBPR binding across MHC I expressed on the surface of cells compared to that found using the SABs ([Figures 2](#fig2){ref-type="fig"}B and 2C). The only exception was HLA-C^∗^01:02, which showed low TAPBPR binding when present at the cell surface ([Figures 2](#fig2){ref-type="fig"}B and 2C). Consistent with the results obtained using the SABs, the top three strongest TAPBPR binders using our cellular system were HLA-A^∗^68:02, A^∗^23:01, and A^∗^02:01 ([Figures 2](#fig2){ref-type="fig"}B and 2C). Strikingly, the binding of TAPBPR to HLA-A^∗^68:02 was ∼7.3- and ∼9-fold higher than to HLA-A^∗^23:01 and A^∗^02:01, respectively. HLA-A molecules belonging to the HLA-A1 and -A3 supertypes exhibited weak/no binding in comparison ([Figures 2](#fig2){ref-type="fig"}B and 2C). Thus, our cellular system confirms the clear preference of TAPBPR for members of the A2 and A24 HLA superfamilies. Among the HLA-B molecules tested, significant TAPBPR binding was only observed to HLA-B^∗^38:01. No binding was observed to the other HLA-B molecules in the panel, including HLA-B^∗^39:01 ([Figures 2](#fig2){ref-type="fig"}B and 2C), which is highly similar to HLA-B^∗^38:01. Taken together, our results using surface-expressed MHC I molecules confirm that TAPBPR exhibits binding preference for MHC I molecules belonging to the HLA-A2 and -A24 superfamilies.

Intracellular Species of MHC I Molecules Confirm TAPBPR-Binding Hierarchy while Revealing Broader Reactivity to TAPBPR {#sec2.4}
----------------------------------------------------------------------------------------------------------------------

Given that, naturally, TAPBPR is an intracellular MHC I chaperone, we next explored the ability of TAPBPR to bind to the total cellular pool of MHC I molecules by performing pull-down experiments by using recombinant TAPBPR on the whole-cell lysates of the panel of HeLaM cell lines expressing each of the 27 different MHC I allotypes ([Figure 3](#fig3){ref-type="fig"}A). Although flow cytometry confirmed the transduced MHC I molecules were well expressed ([Figure 2](#fig2){ref-type="fig"}A; [Figure S2](#mmc1){ref-type="supplementary-material"}), some of the MHC I heavy chains were not reactive to either HC10 or HCA2 antibodies ([Figure 3](#fig3){ref-type="fig"}A). Therefore, the association of β~2~m with TAPBPR was chosen as a surrogate readout for the TAPBPR:MHC I interaction. As expected, we did not observe an association between β~2~m and TAPBPR in HeLaM-HLA-ABC^KO^ cells ([Figure 3](#fig3){ref-type="fig"}A), confirming the lack of β~2~m pulled down directly onto TAPBPR. Using the pull-down system, we observed a similar TAPBPR binding hierarchy for MHC I molecules ([Figure 3](#fig3){ref-type="fig"}A) to that seen using both the SABs ([Figure 1](#fig1){ref-type="fig"}) and the cell surface binding assay ([Figure 2](#fig2){ref-type="fig"}). The pull-down experiments revealed that TAPBPR exhibited the strongest association with HLA-A^∗^68:02 and A^∗^23:01, followed by A^∗^02:01 ([Figure 3](#fig3){ref-type="fig"}A), and that the association of TAPBPR with MHC I occurred in a dose-dependent manner ([Figure S2](#mmc1){ref-type="supplementary-material"}B). Interestingly, when testing the binding of recombinant TAPBPR to the total cellular pool of HLA molecules, we now observed an interaction with some HLA allotypes of the A3 and A1 superfamilies (albeit significantly weaker than those observed with the HLA-A2 and -A24 superfamilies) that did not bind TAPBPR when present at the cell surface, such as A^∗^03:01, A^∗^68:01, A^∗^34:01, and A^∗^25:01 ([Figure 3](#fig3){ref-type="fig"}A). Among the HLA-B molecules tested, TAPBPR appeared to interact mainly with B^∗^38:01, B^∗^08:01, and B^∗^44:05 ([Figure 3](#fig3){ref-type="fig"}A). Finally, HLA-C^∗^01:02 was the only HLA-C molecule tested that showed binding to TAPBPR ([Figure 3](#fig3){ref-type="fig"}A). One likely reason for TAPBPR interacting with a significantly wider panel of MHC I molecules from whole-cell lysates compared to those on the plasma membrane is the availability of peptide-receptive MHC I or of MHC I molecules loaded with sub-optimal peptides. Given that the binding of TAPBPR and peptide to MHC I occurs in a competitive manner ([@bib18], [@bib32], [@bib17]), intracellular MHC I molecules, which contain a higher abundance of peptide-receptive molecules, are presumably more accessible to TAPBPR.Figure 3Intracellular Species of HLA I Molecules Confirm TAPBPR-Binding Hierarchy while Revealing Broader Reactivity to TAPBPRWestern blot analysis on (A) recombinant TAPBPR pull-downs from the lysate of each HLA I-reconstituted HeLaM-HLA-ABC^KO^ cell line and on (B) endogenous TAPBPR and tapasin immunoprecipitates. Membranes were probed with antibodies specific for MHC I heavy chain (using HC10 and HCA2), TAPBPR, tapasin, β~2~m, and calnexin, as indicated. These are representative examples of three independent experiments.

To verify that the relative binding of the different MHC I molecules to TAPBPR was not an artifact of using soluble recombinant TAPBPR, we next isolated endogenous TAPBPR by immunoprecipitation in several of the cell lines from the HeLaM HLA panel. The results were similar to the ones from the pull-down experiment performed with recombinant TAPBPR ([Figure 3](#fig3){ref-type="fig"}B). Namely, HLA-A^∗^68:02 was a much stronger binder to TAPBPR than A^∗^68:01, and binding of HLA-B^∗^38:01 to TAPBPR was considerably stronger than that of B^∗^39:01 ([Figure 3](#fig3){ref-type="fig"}B). However, HLA-B^∗^44:05 exhibited very weak binding to endogenous TAPBPR ([Figure 3](#fig3){ref-type="fig"}B) compared to its binding observed to recombinant TAPBPR. Presumably, this result is due to the lower TAPBPR availability in the cell. These results suggest that MHC I molecules exhibit a wide affinity spectrum for TAPBPR, when considering natural expression levels of TAPBPR in an intracellular environment.

A Similar Hierarchy Is Observed for MHC I Binding to Tapasin {#sec2.5}
------------------------------------------------------------

To shed further light on whether tapasin and TAPBPR work in synergy to shape the MHC I peptide repertoire, we explored whether the interactions of MHC I molecules with tapasin showed any correlation with the interactions observed with endogenous TAPBPR ([Figure 3](#fig3){ref-type="fig"}B). Immunoprecipitation of tapasin from the HeLaM cell panel expressing individual HLA molecules suggested that the HLA I allotypes that exhibited strong binding to TAPBPR were also strong binders to tapasin ([Figure 3](#fig3){ref-type="fig"}B). In the small panel tested, HLA-A^∗^68:02 was the strongest binder to tapasin as well, whereas HLA-A^∗^68:01 interacted weakly with tapasin ([Figure 3](#fig3){ref-type="fig"}B). Both B^∗^44:05 and B^∗^44:02 also interacted weakly with tapasin, as previously observed ([@bib24]), although these two HLA molecules exhibit different dependencies on tapasin ([@bib27], [@bib34]). The strong interaction of HLA-A^∗^68:02 with both tapasin and TAPBPR is in keeping with our previous finding that demonstrated that reglucosylation of this MHC I molecule by UGT1 associated with TAPBPR causes its recycling to the PLC complex ([@bib20]).

The Peptide Exchange Activity of TAPBPR Is Proportional to Its Ability to Bind MHC I {#sec2.6}
------------------------------------------------------------------------------------

Our recent work on a limited number of MHC I molecules suggests that the ability of soluble TAPBPR to bind to cell surface MHC I determines the efficiency of its peptide editing function ([@bib11]). Therefore, we next tested the ability of TAPBPR to catalyze peptide exchange on a broad range of MHC I allotypes by using our recently developed peptide exchange assay on cell surface MHC I molecules ([@bib12]) ([Figure 4](#fig4){ref-type="fig"}A). The MHC I allotypes selected for this experiment included 7 HLA-A, 2 HLA-B, and 2 HLA-C molecules, comprising strong TAPBPR binders (A^∗^68:02, A^∗^02:01, and A^∗^23:01), weak TAPBPR binders (A^∗^32:01, A^∗^03:01, A^∗^11:01, A^∗^68:01, B^∗^38:01, and C^∗^01:02), and non-binders (B^∗^27:05 and C^∗^02:02). We designed fluorescently labeled peptides with high affinity for each of the 11 HLA I allotypes and measured the ability of the specific peptide to bind to HeLaM-HLA-ABC^KO^ cells reconstituted with the corresponding HLA I allotype by flow cytometry, in both the presence or absence of soluble TAPBPR ([Figures 4](#fig4){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}).Figure 4Peptide Exchange Exerted by TAPBPR Is Proportional to Its Ability to Bind HLA I(A) Schematic representation of the TAPBPR-mediated peptide exchange assay on cell surface MHC I molecules. HeLaM-HLA-ABC^KO^ cells expressing individual HLA I allotypes were incubated with the corresponding fluorescently labeled peptides, in the presence of 1 μM TAPBPR.(B) Histograms show levels of fluorescent peptide bound to HLA-A^∗^68:02, A^∗^68:01, and B^∗^27:05, upon treatment without peptide (filled gray line), with peptide alone (black line) or with peptide and TAPBPR (blue line). Histograms depicting fluorescent peptide binding to the other HLA I allotypes tested are shown in [Figure S3](#mmc1){ref-type="supplementary-material"}B.(C) Bar graph summarizing fluorescent peptide binding to various HLA I in the presence of either no TAPBPR (black), 100 nM TAPBPR (orange), or 1 μM TAPBPR (blue).(D) Line graph showing the fold increase in peptide binding to A^∗^68:02, A^∗^02:01, B^∗^38:01, and A^∗^68:01, by TAPBPR at different concentrations.(E) BFA decay rates of the W6/32-reactive HLA I molecules listed in (D), as well as B^∗^27:05 and B^∗^44:05.Error bars show MFI ± SD from three independent experiments. n/s, not significant; ^∗∗^p ≤ 0.01, ^∗∗∗∗^p ≤ 0.0001, using unpaired two-tailed t test.

In the absence of TAPBPR, very low levels of exogenous peptide binding were observed to all MHC I molecules (black line, [Figures 4](#fig4){ref-type="fig"}B and [S3](#mmc1){ref-type="supplementary-material"}B). In the presence of TAPBPR, however, peptide binding was significantly enhanced for the HLA allotypes classified as strong TAPBPR binders (blue line, [Figures 4](#fig4){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}B, and summarized in [4](#fig4){ref-type="fig"}C). The weak TAPBPR binders, namely A^∗^03:01, A^∗^11:01, A^∗^68:01, B^∗^38:01, and C^∗^01:02 still showed a significant enhancement in peptide loading by TAPBPR ([Figures 4](#fig4){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}B, and summarized in [4](#fig4){ref-type="fig"}C); however, this enhancement was significantly lower than the one observed for the strong binders. Peptide loading on the TAPBPR non-binders, B^∗^27:05 and C^∗^02:02, was not enhanced in the presence of TAPBPR ([Figures 4](#fig4){ref-type="fig"}B, [S3](#mmc1){ref-type="supplementary-material"}B, and [4](#fig4){ref-type="fig"}C). None of the peptides tested showed any binding to HeLaM-HLA-ABC^KO^ cells ([Figure S3](#mmc1){ref-type="supplementary-material"}A), confirming that the observed binding of each individual peptide occurred in an MHC I-dependent manner.

To better illustrate the differences in the peptide editing efficiency of TAPBPR across different MHC I allotypes, we measured the dose-dependent effect of TAPBPR on peptide exchange for both strong TAPBPR binders (A^∗^68:02 and A^∗^02:01) and weak binders (B^∗^38:01 and A^∗^68:01). Strikingly, the efficiency of TAPBPR-mediated peptide exchange was considerably higher on HLA-A^∗^68:02 than on the other MHC I allotypes tested, including A^∗^02:01 ([Figure 4](#fig4){ref-type="fig"}D). Namely, in the presence of 100 nM TAPBPR, an 80-fold increase in peptide loading on A^∗^68:02 was observed compared to when peptide was added alone, a 20-fold increase was observed for A^∗^02:01, whereas the low binders A^∗^68:01 and B^∗^38:01 only exhibited a \<2.6-fold increase in peptide loading ([Figure 4](#fig4){ref-type="fig"}D). Moreover, TAPBPR reached half maximal effective concentration (EC~50~) for peptide exchange at ∼40 nM on A^∗^68:02, whereas on A^∗^02:01, the EC~50~ of TAPBPR was ∼500 nM ([Figure 4](#fig4){ref-type="fig"}D). Taken together, these findings indicate a general correlation between the ability of TAPBPR to associate with MHC I molecules ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, and [3](#fig3){ref-type="fig"}) and the efficiency of its catalytic activity ([Figure 4](#fig4){ref-type="fig"}). The presence of outliers, such as HLA-A^∗^32:01, is potentially due to specific intrinsic properties of particular MHC I allotypes that will allow TAPBPR to disrupt their binding groove and, thus, facilitate peptide dissociation to a high extent, without needing to form a strong interaction with the MHC I.

The Relative Susceptibility of MHC I Molecules to Undergo Peptide Editing by TAPBPR Does Not Correlate with Their Relative Stability at the Cell Surface {#sec2.7}
--------------------------------------------------------------------------------------------------------------------------------------------------------

Given that each MHC I allotype will naturally present a distinct peptide repertoire, the stability of pMHC I complexes present at the cell surface may differ significantly among different MHC I allotypes. Thus, we next questioned whether the observed hierarchy regarding MHC I susceptibility to TAPBPR-mediated peptide exchange correlated with the relative stability of the MHC I molecules at the cell surface. By performing Brefeldin A (BFA) decay experiments on a few MHC I allotypes spanning the entire TAPBPR binding hierarchy ([Figure 2](#fig2){ref-type="fig"}C), we found that HLA-A^∗^68:02, the strongest HLA I binder to TAPBPR, displayed the highest decay rate from the cell surface and, hence, the lowest stability among the allotypes tested ([Figure 4](#fig4){ref-type="fig"}E). In contrast, the weak TAPBPR binders B^∗^44:05 and B^∗^27:05 showed the highest relative stability among the molecules tested ([Figure 4](#fig4){ref-type="fig"}E). Based on this comparison alone, TAPBPR binding could appear to correlate with MHC I stability. However, highly similar decay rates were observed for A^∗^02:01 and for A^∗^68:01, which are at opposite ends of the TAPBPR binding hierarchy ([Figure 4](#fig4){ref-type="fig"}E). Moreover, HLA-B^∗^38:01 showed a lower stability than A^∗^02:01, despite its considerably weaker susceptibility to peptide editing by TAPBPR ([Figure 4](#fig4){ref-type="fig"}E). Overall, although the molecular stability of MHC I molecules may influence their propensity to undergo peptide editing by TAPBPR, this process appears to be driven mainly by the intrinsic ability of the MHC I to associate with TAPBPR.

Molecular Features of the F Pocket Correlate with MHC I Binding to TAPBPR {#sec2.8}
-------------------------------------------------------------------------

We have previously proposed that F pocket specificity for hydrophobic amino acids is a key requirement of MHC I molecules for undergoing efficient TAPBPR-mediated peptide exchange ([@bib11]). Thus, we explored the molecular basis of the observed TAPBPR preference for the HLA-A2 and -A24 supertype members, focusing first on the MHC I F pocket. Our comparisons revealed that all members of the HLA-A2 and -A24 superfamilies exhibit F pocket specificity for hydrophobic amino acids ([Table S2](#mmc1){ref-type="supplementary-material"}) ([@bib29]). In contrast, all members of the A3 superfamily accommodate a basic residue at this site ([Table S2](#mmc1){ref-type="supplementary-material"}). Naturally, we next compared the residues involved in determining the F pocket specificity, found between positions 72 and 120 ([@bib29]), among different HLA-A molecules ([Figure 5](#fig5){ref-type="fig"}A). Interestingly, we found residues H114 and Y116 to be conserved across all members of the A2 and A24 superfamilies ([Table S2](#mmc1){ref-type="supplementary-material"}; [Figure 5](#fig5){ref-type="fig"}A). Moreover, none of the other HLA I molecules currently known exhibit this combination of residues at the specified positions. Taken together, these correlations, based on a wide panel of HLA I allotypes, suggest that the susceptibility of HLA I molecules to TAPBPR-mediated peptide editing may be strongly influenced by the architecture of the MHC I F pocket ([@bib11]).Figure 5H114/Y116 Residue Combination Is Conserved Exclusively across All HLA I Members of the A2 and A24 Superfamilies(A) Amino acid sequence alignment across members of all HLA-A superfamilies, spanning residues 1--12 and 72--120; residues 114 and 116 (red) as well as residues 12 and 105 (blue) were highlighted.(B) PyMOL image of the structure of HLA-A^∗^68:02 folded with peptide SVYDFFVWL (PDB ID [4HX1](pdb:4HX1){#intref0025}); residues H114 and Y116 are highlighted in red, the L9 residue of the peptide in light blue, and the peptide backbone in gray. Dotted yellow lines indicate the shortest distances between the connected amino acid residues, measured in Å.

The F Pocket Architecture Governs the Ability of MHC I Molecules to Associate with TAPBPR {#sec2.9}
-----------------------------------------------------------------------------------------

We predicted that the combination of residues H114/Y116 was responsible for the strong interaction observed between MHC I and TAPBPR, by enabling an open conformation of the hydrophobic F pocket, accessible to the L30 residue of TAPBPR ([Figure 5](#fig5){ref-type="fig"}B). To test this, we artificially reconstituted these residues into several MHC I molecules. Although there are no HLA-B or -C allotypes that contain the H114/Y116 residue combination, HLA-B^∗^27:05, for instance, contains H114 but D116 instead of Y116, and HLA-B^∗^44:05 contains Y116 but D114 instead of H114 ([Figure 6](#fig6){ref-type="fig"}A). We, therefore, replaced D114 with a histidine in HLA-B^∗^44:05 and replaced D116 with a tyrosine in HLA-B^∗^27:05 ([Figure 6](#fig6){ref-type="fig"}A). Both HLA-B^∗^44:05^D114H^ and B^∗^27:05^D116Y^ showed very similar surface expression levels compared to their corresponding wild-type (WT) molecules when reconstituted into HeLaM-HLA-ABC^KO^ cells ([Figure S4](#mmc1){ref-type="supplementary-material"}A).Figure 6Residues H114/Y116 Promote Association of HLA-A, -B, and -C Molecules to TAPBPR(A) Amino acid sequence alignment comparing residues 72--120 of A^∗^68:02 with the ones of A^∗^68:01, B^∗^44:05, and B^∗^27:05 and their corresponding F pocket mutants; residues 114 and 116 are highlighted in red.(B) Bar graph shows TAPBPR binding to cells expressing each HLA I allotype in (A), either WT (blue) or mutant (red), based on three independent experiments.(C) Bar graph shows the binding of fluorescent peptide SRYWK^∗^IRTR to cells expressing either B^∗^27:05^WT^ or B^∗^27:05^D116Y^ and of EEFGK^∗^AFSF to cells expressing either B^∗^44:05^WT^ or B^∗^44:05^D114H^ upon treatment with peptide and either no TAPBPR (black), 100 nM TAPBPR (orange), or 1 μM TAPBPR (blue).(D) Line graph comparing the BFA decay rates of W6/32-reactive WT and mutated HLA I molecules.(E) Bar graph showing the level of the fluorescent peptide SRYWK^∗^IRTR to cell surface B^∗^27:05 or B^∗^27:09 and of SPAIK^∗^QSSM to B^∗^35:01 or B^∗^35:03, when cells were treated either with peptide alone (gray bar) or peptide and 1 μM TAPBPR (blue bar). For expression levels of these HLA-I molecules, either at the cell surface or in the cell, see [Figures S5](#mmc1){ref-type="supplementary-material"}B and S5C, respectively.Error bars show MFI ± SD from three independent experiments. n/s, not significant; ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, ^∗∗∗^p ≤ 0.001, ^∗∗∗∗^p ≤ 0.0001 using unpaired two-tailed t test.

When assessing their ability to bind TAPBPR, we found that neither B^∗^27:05^WT^ nor B^∗^44:05^WT^ associated significantly with TAPBPR at the cell surface ([Figure 6](#fig6){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}B). In stark contrast, both HLA-B^∗^27:05^D116Y^ and B^∗^44:05^D114H^ displayed a high level of TAPBPR binding ([Figure 6](#fig6){ref-type="fig"}B; [Figure S4](#mmc1){ref-type="supplementary-material"}B), as was also observed when A^∗^68:02-like F pocket was reconstituted into A^∗^68:01 ([Figure 6](#fig6){ref-type="fig"}B), as previously shown ([@bib11]). TAPBPR pull-down experiments using whole-cell lysates verified these findings, while also demonstrating increased interaction between TAPBPR and HLA-C^∗^01:02 upon introducing the H114/Y116 combination ([Figure S4](#mmc1){ref-type="supplementary-material"}C). Moreover, disturbing the H114/Y116 F pocket combination of the strong TAPBPR binder A^∗^68:02, by mutating Y116→D, triggered a severe decrease in TAPBPR binding ([Figures 6](#fig6){ref-type="fig"}B and [S4](#mmc1){ref-type="supplementary-material"}D). These findings demonstrate that the H114/Y116 combination is a key determinant in the ability of HLA I molecules to interact with TAPBPR.

Interestingly, in addition to their stronger association with TAPBPR, HLA-A^∗^68:01^D116Y^ and B^∗^44:05^D114H^ showed a similar enhancement in their ability to bind tapasin compared to their WT counterparts ([Figure S4](#mmc1){ref-type="supplementary-material"}C). This suggests there may be a correlation between the interaction of MHC I molecules with TAPBPR and their net binding to tapasin, similar to the one observed for the panel of WT HLA I molecules tested above ([Figure 3](#fig3){ref-type="fig"}B).

MHC I Susceptibility to TAPBPR-Mediated Peptide Editing Is Strongly Influenced by the F Pocket Architecture {#sec2.10}
-----------------------------------------------------------------------------------------------------------

We next explored whether the alterations made to the F pocket of HLA-B^∗^44:05 and B^∗^27:05 increased their susceptibility to TAPBPR-mediated peptide exchange. In the presence of TAPBPR, peptide binding to HLA-B^∗^27:05 was not increased, whereas on HLA-B^∗^44:05^WT^, a slight enhancement was observed compared to peptide alone ([Figures 6](#fig6){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}E). Strikingly, however, introducing an A^∗^68:02-like F pocket in both HLA-B^∗^44:05 and B^∗^27:05 triggered a ∼100-fold increase in peptide loading by TAPBPR ([Figures 6](#fig6){ref-type="fig"}C and [S4](#mmc1){ref-type="supplementary-material"}E), to levels comparable to the ones observed for HLA-A^∗^02:01 and A^∗^68:02 molecules ([Figure 4](#fig4){ref-type="fig"}C). Upon testing whether the F pocket mutations altered the molecular stability of the MHC I molecules by using BFA decay assays, we observed that HLA-B^∗^44:05^D114H^ displayed significantly lower stability at the cell surface than -B^∗^44:05^WT^, whereas B^∗^27:05^D116Y^ was, surprisingly, more stable than B^∗^27:05^WT^ ([Figure 6](#fig6){ref-type="fig"}D). Furthermore, mutating the F pocket of A^∗^68:02 (A^∗^68:02^Y116D^) generated a slightly less stable molecule ([Figure 6](#fig6){ref-type="fig"}D), despite also severely impairing its ability to bind TAPBPR ([Figure 6](#fig6){ref-type="fig"}B). This further confirms that TAPBPR binding and peptide exchange on MHC I appear to be driven mainly by intrinsic properties of the MHC I rather than by the molecular stability of MHC I. Together, these findings indicate that residues H114 and Y116, in combination, represent a key molecular signature responsible for the high susceptibility observed for the HLA I members of the A2 and A24 supertypes to TAPBPR-mediated peptide exchange.

Natural Polymorphisms at Position 116 Influence the Propensity of HLA-B Molecules to Undergo TAPBPR-Mediated Peptide Editing {#sec2.11}
----------------------------------------------------------------------------------------------------------------------------

Having shown that artificially mutating residue 116 in HLA-B^∗^27:05 dramatically increased it susceptibility to TAPBPR-mediated peptide editing, we next tested whether naturally occurring polymorphisms in HLA-B^∗^27 at this position also influenced its ability to undergo peptide exchange. To this end, we assessed the ability of HLA-B^∗^27:05 and B^∗^27:09, which only differ in residue 116 (D→H) ([Figure S5](#mmc1){ref-type="supplementary-material"}A) to undergo TAPBPR-mediated peptide exchange by testing their ability to bind to a fluorescent derivative of SRYWAIRTR (SRYWK^∗^IRTR), which was shown to bind to both B^∗^27:05 and B^∗^27:09 ([@bib21]). Although TAPBPR showed no significant effect on peptide binding to HLA-B^∗^27:05, it facilitated an enhancement of over 100% in the level of peptide exchange on HLA-B^∗^27:09 ([Figure 6](#fig6){ref-type="fig"}E). Next, we compared the ability of TAPBPR to mediate peptide exchange on another MHC I pair that also differs in residue 116 alone, namely HLA-B^∗^35:01 and -B^∗^35:03 (S116→F) ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Consequently, we tested the ability of TAPBPR to load a fluorescent derivative of SPAIFQSSM (SPAIK^∗^QSSM), which was previously found to bind to both HLA-B35 molecules (HIV Molecular Immunology epitope database). Although the level of peptide exchange on HLA-B^∗^35:01 was unaffected by TAPBPR, a slight (∼20%) but significant increase in peptide loading onto B^∗^35:03 was observed in the presence of TAPBPR ([Figure 6](#fig6){ref-type="fig"}E). As expected, given that none of these HLA-B molecules contain the H114/Y116 motif, the ability of TAPBPR to mediate peptide exchange on them was significantly lower compared to HLA-A2 and -A24 superfamily members. However, the one amino acid difference, at the key position 116, between the HLA-B^∗^27 allotypes as well as between the HLA-B^∗^35 allotypes, appears to be enough to cause a difference in the propensity of those molecules to undergo TAPBPR-mediated peptide editing.

M12 Residue, Present in HLA-A^∗^68:02, Is Responsible for Its Distinct Ability to Interact with TAPBPR {#sec2.12}
------------------------------------------------------------------------------------------------------

Our data using both the SABs ([Figure 1](#fig1){ref-type="fig"}) and the cellular system ([Figure 2](#fig2){ref-type="fig"}) suggest that, although all members of the HLA-A2 and -A24 supertypes interact with TAPBPR, HLA-A^∗^68:02 is by far the strongest TAPBPR binder. This implies that residues unique to HLA-A^∗^68:02, apart from the ones found in the F pocket, enhance its ability to bind to TAPBPR. A comparison of the amino acid sequence of HLA-A^∗^68:02 with the weak TAPBPR binder HLA-A^∗^68:01 revealed that, in addition to residues determining the specificity of the F pocket (positions 97, 114, and 116), there are differences between these two MHC I allotypes at positions 12 and 105 ([Figures 5](#fig5){ref-type="fig"}A and [7](#fig7){ref-type="fig"}A). Furthermore, among all members of the A2 and A24 superfamilies tested in this study, residues M12 and P105 were unique to HLA-A^∗^68:02 ([Figure 7](#fig7){ref-type="fig"}A). For instance, HLA-A^∗^69:01 shows a considerably lower ability to bind TAPBPR ([Figure 1](#fig1){ref-type="fig"}), although it differs from A^∗^68:02 in only a few amino acids, including those at positions 12 and 105 ([Figures 5](#fig5){ref-type="fig"}A and [7](#fig7){ref-type="fig"}A). We, therefore, hypothesized that residues M12 and/or P105 were responsible for the pronounced ability of HLA-A^∗^68:02 to bind to TAPBPR. To test this, we swapped either residue 12 or 105 between HLA-A^∗^68:02 and -A^∗^02:01, resulting in the following mutants: A^∗^68:02^M12V^, A^∗^68:02^P105S^, A^∗^02:01^V12M^, and A^∗^02:01^S105P^. Upon reconstitution into HeLaM-HLA-ABC^KO^ cells, all four MHC I mutants showed similar surface expression as their WT counterparts ([Figure 7](#fig7){ref-type="fig"}B). When assessing the ability of these altered MHC I molecules to bind recombinant TAPBPR, we found that the mutation of residue 105 in either HLA-A^∗^68:02 or A^∗^02:01 had no significant effect on their ability to bind to TAPBPR ([Figures 7](#fig7){ref-type="fig"}C and 7D). Strikingly, however, the mutation of residue M12 in HLA-A^∗^68:02 resulted in a 10-fold decrease in TAPBPR binding ([Figures 7](#fig7){ref-type="fig"}C and 7D). Furthermore, the corresponding V12M mutation in HLA-A^∗^02:01 resulted in a \>10-fold increase in TAPBPR binding ([Figures 7](#fig7){ref-type="fig"}C and 7D), to levels almost identical to those observed for A^∗^68:02^WT^ ([Figures 7](#fig7){ref-type="fig"}C and 7D). These findings suggest that the M12 residue, uniquely present in HLA-A^∗^68:02, is responsible for its distinct ability to interact with TAPBPR.Figure 7M12 Residue, Found Specifically in HLA-A^∗^68:02, Promotes Its Accessibility to TAPBPR(A) PyMOL figures highlighting amino acid differences between A^∗^68:02 and A^∗^68:01 (left), A^∗^69:01 (center), and A^∗^02:01 (right), respectively; conserved residues are colored in blue, different residues between A^∗^68:02 and A^∗^68:01 in red, and differences between A^∗^68:02 and other strong binders in green.(B) Histograms showing cell surface levels of A^∗^68:02^WT^, A^∗^68:02^M12V^, A^∗^68:02^P105S^, A^∗^02:01^WT^, A^∗^02:01^V12M^, and A^∗^02:01^S105P^.(C) Histograms show TAPBPR binding to the HLA I variants in (B), after cells were treated with 100 nM TAPBPR for 30 min.(D) Bar graphs showing TAPBPR binding to the HLA I allotypes tested in (C), upon treatment with either 100 nM (light gray) or 1 μM TAPBPR (dark gray).Bars show MFI ± SD from three independent experiments. n/s, not significant; ^∗^p ≤ 0.05, ^∗∗∗∗^p ≤ 0.0001 using unpaired two-tailed t test.

Discussion {#sec3}
==========

Here, we perform a large-scale study to explore which MHC I molecules interact with, and are consequently edited by, TAPBPR. We reveal a striking binding preference of TAPBPR for HLA-A allotypes, particularly for the members of the A2 and A24 superfamilies, over HLA-B and -C molecules. Our findings are in keeping with the limited number of HLA I molecules previously tested in TAPBPR binding and peptide exchange assays, namely HLA-A^∗^02:01, A^∗^68:02, B^∗^08:01, and A^∗^01:01 ([@bib9], [@bib11], [@bib12], [@bib18]).

Although the unique peptide repertoires bound to the various MHC I molecules may influence their molecular stability and, consequently, influence their propensity to undergo peptide editing by TAPBPR, our findings suggest that TAPBPR-mediated peptide editing is largely driven by the intrinsic ability of the MHC I to bind TAPBPR. Specifically, the molecular features of the MHC I F pocket appear to strongly influence the ability of MHC I to bind to TAPBPR. We show that the preference of TAPBPR for A2 and A24 HLA supertypes is due to their F pocket specificity for hydrophobic amino acid residues. Our findings are consistent with our previously proposed model that suggests that TAPBPR mediates efficient peptide exchange on MHC I by using its L30 residue to catalyze the dissociation of the C-terminal anchor residue of the peptide from the MHC I F pocket ([@bib11]). Furthermore, our results establish that the residues found at positions 114 and 116 of MHC I are crucial for the observed allotype preference of TAPBPR for HLA I.

Interestingly, studies exploring tapasin function across a range of HLA I molecules, particularly HLA-B molecules, have previously proposed that residues 114 and 116 also affect MHC I dependency on tapasin ([@bib24], [@bib25], [@bib27], [@bib34]). Our results, based on a limited number of HLA I molecules, suggest that tapasin might display a similar HLA preference as TAPBPR. Although there appear to be shared features between tapasin and TAPBPR in terms of their MHC I preference and their proposed catalytic mechanisms ([@bib6], [@bib11], [@bib17], [@bib32]), there seems to be an obvious difference between the two peptide editors; although TAPBPR binding and peptide exchange is strongly dependent on F pocket specificity for hydrophobic amino acids, this does not appear to be the case for tapasin ([@bib27], [@bib34], [@bib24]). Moreover, tapasin and TAPBPR are likely to access distinct pools of MHC I in terms of glycan attachment ([@bib19]) and peptide affinity. Together, these findings indicate that the role of these two peptide editors on MHC I is likely to differ significantly. Although tapasin enables loading of peptide-receptive MHC I molecules, we speculate that TAPBPR plays a more significant role in dissociating peptides from MHC I that have already gone through PLC-mediated peptide selection but are sub-optimal for presentation. To fulfil this purpose, in addition to the higher intrinsic affinity of TAPBPR for selected MHC I relative to tapasin, TAPBPR has developed a highly specialized loop region ([@bib11], [@bib32]) that allows it to dissociate stably bound peptides, which are no longer accessible to tapasin. Consequently, TAPBPR has a stronger influence on MHC I molecules compatible with its functional region involved in peptide dissociation.

Apart from residues found in the F pocket, other polymorphisms in MHC I molecules will inevitably affect their susceptibility to TAPBPR. Here, we reveal that residue M12, found uniquely in HLA-A^∗^68:02 among all HLA-A molecules tested, facilitates the accessibility of this allotype to TAPBPR. It is currently unclear how this subtle difference in one amino acid makes HLA-A^∗^68:02 such a compatible ligand for TAPBPR. Modeling of this HLA-A molecule onto the solved crystal structure of human TAPBPR with mouse MHC I ([@bib13], [@bib32]) does not support a direct interaction between TAPBPR and MHC I at this site ([Figure S6](#mmc1){ref-type="supplementary-material"}). It is possible that residue M12 affects the interaction between the heavy chain of A^∗^68:02 and β~2~m, potentially influencing the conformational plasticity of the MHC I complex ([Figure S6](#mmc1){ref-type="supplementary-material"}), which was recently proposed to drive chaperone recognition ([@bib17]).

In a biological context, our results suggest that HLA molecules accommodating basic/charged amino acids in their F pocket do not require extensive peptide editing by TAPBPR. In contrast, HLA-A molecules accommodating hydrophobic amino acids in this pocket appear to undergo significant peptide editing by TAPBPR. This could be due to both a wider availability of peptides carrying hydrophobic amino acids at their C terminus in the endoplasmic reticulum (ER) and an increased peptide-binding promiscuity of HLA-A2 and -A24 superfamily members, which would consequently require more stringent peptide selection. Given the preference of TAPBPR for HLA-A molecules over HLA-B and -C molecules, it is interesting to speculate whether rigorous peptide editing is required for MHC I molecules predominantly monitored by the T cell receptor, compared to those monitored by additional receptors on natural killer cells, such as the killer cell immunoglobulin-like receptors.

Interestingly, we have revealed that the subtle polymorphisms found in specific MHC I molecules associated with disease influence their ability to undergo TAPBPR-mediated peptide exchange. Although HLA-B^∗^27:05 and -B^∗^27:04 are strongly associated with ankylosing spondylitis (AS), HLA-B^∗^27:06 and HLA-B^∗^27:09 are either not or only weakly associated with AS. Here, we reveal that natural variations in residue 116 of these HLA-B27 molecules, which appear to correlate with disease susceptibility, impact their ability to undergo peptide editing by TAPBPR. Furthermore, we found that a difference in residue 116 between two MHC I molecules that are associated with different progression rates of HIV, HLA-B^∗^35:01, and B^∗^35:03, also influence their susceptibility to TAPBPR-mediated peptide editing. It is worth bearing in mind that our assays monitor the ability of TAPBPR to mediate peptide exchange on MHC I expressed on the cell surface, which have already passed through quality-control checkpoints. The magnitude of TAPBPR-mediated peptide editing on these specific MHC I molecules may be even greater when in its natural intracellular setting. Given that peptide selection likely plays an important role linking the association of specific MHC I molecules to infectious diseases and autoinflammatory conditions, our findings may offer new insight regarding how a apparently subtle variation in MHC I can have a significant impact on susceptibility to disease.

Regardless of its biological significance, the function of TAPBPR can be exploited to load immunogenic peptides onto surface-expressed MHC I molecules ([@bib12]). Therefore, there may be a possibility to utilize recombinant TAPBPR for immunotherapeutic applications in the future, which may prove beneficial for increasing tumor immunogenicity. Our findings here suggest that a relatively broad range of HLA-A molecules, found at significant frequencies worldwide, are potentially targetable for exogenous peptide loading by human TAPBPR. The knowledge gained here may also prove informative regarding how to engineer TAPBPR to increase its compatibility and efficiency for an even wider range of MHC I molecules.

STAR★Methods {#sec4}
============

Key Resources Table {#sec4.1}
-------------------

REAGENT or RESOURCESOURCEIDENTIFIER**Antibodies**Anti-TAPBPR mAb, PeTe4[@bib2]N/AAnti-TAPBPR mAbabcamCat\# ab57411Anti-tapasin Pasta-1Gift from Peter CresswellN/AAnti-tapasin R.gp48NGift from Peter CresswellN/AHC10[@bib30]N/AHCA2[@bib31]N/AAnti-human β~2~mDakoCat\# A0072W6/32[@bib1]N/AAnti-calnexin mAbEnzo Life SciencesCat\# ADI-SPA-860; RRID: [AB_10616095](nif-antibody:AB_10616095){#interref30}Mouse IgG2A isotype controlSigma-AldrichCat\# X0943Goat anti-mouse Alexa Fluor 647 IgGInvitrogen Molecular Probes, Thermo Fisher ScientificCat\# A21236; RRID: [AB_2535805](nif-antibody:AB_2535805){#interref35}**Chemicals, Peptides, and Recombinant Proteins**FuGENEPromegaCat\# E2311Hexadimethrine bromideSigma-AldrichCat\# H9268ETVSK(5TAMRA)QSNV peptidePeptide SyntheticsN/AYLLEK(5TAMRA)LWRL peptidePeptide SyntheticsN/AKTGGPIYK(5TAMRA)R peptidePeptide SyntheticsN/APYLFK(5TAMRA)LAAI peptidePeptide SyntheticsN/ARVLDK(5TAMRA)VEKW peptidePeptide SyntheticsN/ASRYWK(5TAMRA)IRTR peptidePeptide SyntheticsN/ASHETK(5TAMRA)IIEL peptidePeptide SyntheticsN/ASPAIK(5TAMRA)QSSM peptidePeptide SyntheticsN/AEEFGK(5TAMRA)AFSF peptidePeptide SyntheticsN/ALNPSK(5TAMRA)AATL peptidePeptide SyntheticsN/ARecombinant soluble TAPBPR WT[@bib12]N/ARecombinant soluble TAPBPR TN5 mutant[@bib12]N/A**Critical Commercial Assays**LABScreen Single Antigen HLA Class I CQ14NC7, Lot 011-- HLAF Catalog FileOne Lambda, Inc., CA, USACat\# LS1A04**Experimental Models: Cell Lines**HEK293T[@bib19]N/AHeLaM-HLA-ABC^KO^[@bib19]N/A**Oligonucleotides**Primers for HLA class I mutants, see Table S3This paperN/A**Recombinant DNA**pHRSINcPPT-SGW[@bib2]N/APiggyBac transposon vector[@bib12]N/AcDNA of HLA I allelesKind gifts from Peter Parham, Elisabeth Chalmeau, Jane Goodall, Ashley Moffett, Sebastian Springer, Rajiv Khanna and Jim McCluskeyN/A**Software and Algorithms**HLA Fusion™ softwareOne Lambda, Inc., CA, USA<https://www.onelambda.com/en/product/hla-fusion.html>

Lead Contact and Materials Availability {#sec4.2}
---------------------------------------

Further information and requests for reagents may be directed to and will be fulfilled by the Lead Contact, Louise H. Boyle (<lhb22@cam.ac.uk>).

This study did not generate new unique reagents.

Experimental Model and Subject Details {#sec4.3}
--------------------------------------

The human cell lines HeLaM-HLA-ABC^KO^, generated as previously described ([@bib19]), and HEK293T were maintained in Dulbecco's Modified Eagle's medium (DMEM; Sigma-Aldrich, UK) supplemented with 10% fetal bovine serum (FBS) (GIBCO, Thermo Fisher Scientific), 100 U/ml penicillin and 100 μg/ml streptomycin (GIBCO, Thermo Fisher Scientific), at 37°C with 5% CO~2~.

Method Details {#sec4.4}
--------------

### Constructs {#sec4.4.1}

cDNA templates for a large panel HLA I molecules were kind gifts from Peter Parham (Stanford University), Elisabeth Chalmeau (University Nantes, France), Jane Goodall (University of Cambridge, UK), Ashley Moffett (University of Cambridge, UK), Sebastian Springer (Jacobs University, Bremen, Germany), Rajiv Khanna (Queensland Institute of Medical Research, Australia) and Jim McCluskey (University of Melbourne, Australia). These were amplified and cloned into the lentiviral vector pHRSINcPPT-SGW, as previously described ([@bib2]). The mutant HLA I constructs A^∗^68:02^Y116D^, A^∗^02:01^Y116D^ and A^∗^68:01^D114H^ were generated as previously described ([@bib11]). The mutant constructs A^∗^02:01^V12M^, A^∗^02:01^S105P^, A^∗^68:02^M12V^, A^∗^68:02^P105S^, B^∗^44:05^D114H^ and C^∗^01:02^D114H^ were generated by quick-change PCR, using primers shown in [Table S3](#mmc1){ref-type="supplementary-material"}. All HLA I mutants were cloned into the pHRSINcPPT-SGW vector. The luminal domains of TAPBPR WT and TAPBPR TN5 mutant ([@bib9]) were cloned in a PiggyBac transposon vector, as previously described ([@bib12]), to produce a secreted version of TAPBPR, containing a polyHis tag at the C terminus, in a mammalian expression system.

### Lentiviral transductions {#sec4.4.2}

All cells derived from the HeLaM-HLA-ABC^KO^ line, were transduced using lentivirus as previously described ([@bib19]); lentivirus-containing supernatant collected from HEK293T cells was added to HeLaM-HLA-ABC^KO^ cells in the presence of 8 μg/mL Hexadimethrine bromide (Sigma-Aldrich). To induce expression of endogenously-expressed TAPBPR and upregulate the surface expression of MHC I molecules, HeLaM-derived cell lines were treated with 200 U/ml IFN-γ (Peprotech, UK) for 48--72 h.

### Antibodies {#sec4.4.3}

TAPBPR was detected using either PeTe4, a mouse monoclonal antibody (mAb) specific for the native conformation of TAPBPR, raised against amino acids 22--406 of human TAPBPR ([@bib2]) that does not cross-react with tapasin ([@bib8]), or ab57411, a mouse mAb raised against amino acids 23--122 of TAPBPR that is reactive to denatured TAPBPR (Abcam, UK). Tapasin was detected using Pasta-1 ([@bib4]), or with R.gp48N, a rabbit polyclonal antibody specific for tapasin ([@bib28]) (kind gifts from Peter Cresswell, Yale University School of Medicine). MHC I heavy chains were detected using mAb HC10 ([@bib30]) and mAb HCA2 ([@bib31]). β~2~m was detected using a rabbit polyclonal antibody (Dako, UK). Cell surface MHC I molecules were detected using W6/32, a pan-MHC I mAb that recognizes a conformational epitope on the α2 domain of MHC I, in a manner dependent on presence of β~2~m and peptide ([@bib1]). Calnexin was detected via western blot analysis using the rabbit polyclonal ADI-SPA-860 (Enzo Life Sciences, UK). A mouse IgG2a isotype control was also used as a control (Sigma-Aldrich).

### MHC I-binding peptides {#sec4.4.4}

Peptides specific to individual HLA I allotypes were selected using SYFPEITHI database and/or Immune Epitope Database and Analysis Resource. The following MHC I-specific peptides were used: ETVSK^∗^QSNV (K^∗^ represents a lysine labeled with 5-carboxytetramethylrhodaime \[TAMRA\]), derived from the HLA-A^∗^68:02-specific peptide ETVSEQSNV ([@bib11]); YLLEK^∗^LWRL, derived from the HLA-A^∗^02:01-specific peptide YLLEMLWRL ([@bib11]); KTGGPIYK^∗^R, derived from the HLA-A^∗^68:01-specific peptide KTGGPIYKR ([@bib11]); PYLFK^∗^LAAI, derived from the HLA-A^∗^23:01-specific peptide PYLFWLAAI; RVLDK^∗^VEKW, with predicted high affinity for HLA-A^∗^32:01; SRYWK^∗^IRTR, derived from the HLA-B^∗^27:05-specific peptide SRYWAIRTR; SPAIK^∗^QSSM, derived from the HLA-B35 and -B7-specific peptide SPAIFQSSM; SHETK^∗^IIEL, derived from the HLA-B^∗^38:01-specific peptide *SHETVIIEL*; EEFGK^∗^AFSF, derived from the HLA-B^∗^44:05-specific peptide *EEFGRAFSF*; LNPSK^∗^AATL, derived from the HLA-C^∗^01:02-specific peptide LNPSVAATL. All peptides were purchased from Peptide Synthetics, UK.

### Expression and purification of TAPBPR protein {#sec4.4.5}

The secreted forms of TAPBPR WT and of TAPBPR TN5 mutant (luminal domain alone), carrying a C-terminal polyHis tag, was expressed in HEK293T cells, using the Piggy Bac expression system, as previously described ([@bib12]).

### Flow cytometry {#sec4.4.6}

Following trypsinization, cells were washed in 1% BSA solution in 1xPBS, at 4°C. Cells were then stained for 30 min, at 4°C, with one of the following antibodies: PeTe4, W6/32 or an isotype control antibody. After two subsequent rounds of washing with 1% BSA solution to remove any excess of unbound antibody, cells were stained for 30 min, at 4°C, with a goat anti-mouse Alexa Fluor 647 IgG (Invitrogen Molecular Probes, Thermo Fisher Scientific). Following another three rounds of washing, the fluorescence levels were detected using a BD FACScan analyzer with Cytek modifications. The analysis was performed using FlowJo (FlowJo, LLC, Ashland, OR).

### Peptide binding assays {#sec4.4.7}

HeLaM cells were seeded in 12-well plates, at 2.5-3.0^∗^10^4^/well, and stimulated with 200 U IFN-γ for 48 h. Cells were then washed with 1x PBS and then incubated in opti-MEM (GIBCO, Thermo Fisher Scientific), at physiological pH, with either 100 nM or 1 μM TAPBPR at 37°C. After 15 min, fluorescently labeled peptide was added to the cells, at different concentrations (10 nM for A^∗^68:02, A^∗^02:01, A^∗^23:01, A^∗^32:01, B^∗^44:05 and 100 nM for A^∗^68:01, A^∗^03:01, A^∗^11:01, B^∗^27:05, B^∗^38:01, C^∗^01:02, C^∗^02:02) and for different time periods (15 min for A^∗^68:02, A^∗^23:01 and 60 min for A^∗^02:01, A^∗^32:01, A^∗^68:01, A^∗^03:01, A^∗^11:01, B^∗^27:05, B^∗^38:01, B^∗^44^∗^05, C^∗^01:02, C^∗^02:02), depending on the HLA I allotype expressed. Cells were then washed three times in 1x PBS to remove any excess of unbound TAPBPR and peptide. After cells were harvested, the level of fluorescent peptide bound was measured by flow cytrometry, using the YelFL1 channel (Cytek).

### BFA decay assays {#sec4.4.8}

IFN-γ-stimulated HeLa-HLA-ABC^KO^ cells, reconstituted with individual HLA I allotypes were treated with 10 μg/mL BFA (Sigma-Aldrich) for different time periods. Cells were then harvested and the levels of MHC class I molecules present at the surface of each cell line, at each time point, were measured by flow cytometry, by staining with the W6/32 antibody.

### Single antigen bead screen {#sec4.4.9}

3 μL of the LABScreen® single antigen HLA bead suspension (One Lambda, Inc., CA, USA) was added per well of a 96-well plate and incubated with either 100 nM or 1 μM soluble WT TAPBPR, or with 1 μM TAPBPR TN5 mutant, at 22°C, with rotation, for 60 min. The beads were washed three times in wash buffer (One Lambda, Inc., CA, USA) to remove any excess of soluble TAPBPR and were then first incubated with PeTe4 antibody for 30 min, washed and then incubated with a PE-conjugated goat anti-mouse IgG (Abcam, UK) for another 30 min at 22°C. After a subsequent round of washing, cells were re-suspended in 1x PBS and the TAPBPR levels bound to the beads were measured by a using the Luminex Fluoroanalyser system (One Lambda, Inc., CA, USA) and analyzed using the HLA FusionTM software (One Lambda, Inc., CA, USA).

### Immunoprecipitation, gel electrophoresis and western blotting {#sec4.4.10}

5x10^6^ IFN-γ-stimulated HeLaM-HLA-ABC^KO^ cells reconstituted with each HLA I molecule were harvested and washed in PBS. Cells were then lysed either in 1% Triton X-100 (VWR, Radnor, PN) in Tris-buffered saline (TBS) (20 mM Tris-HCl, 150 mM NaCl, 2.5 mM CaCl~2~), whenever TAPBPR was pulled down, or in 1% digitonin (Merck, MA, USA) in TBS, whenever tapasin was pulled down, supplemented with 10 mM NEM, 1 mM phenylmethylsulfonyl fluoride (PMSF) (Sigma-Aldrich), and protease inhibitor cocktail (Roche, UK), for 30 min at 4°C. Nuclei and debris were removed by centrifugation at 13,000 x g for 15 min. For the recombinant TAPBPR pull-down experiments, 2 μg of TAPBPR was added per sample and incubated for 1 h at 4°C with rotation, following which TAPBPR was pulled down with beads pre-coated with 5 μg PeTe4 antibody/sample, again for 1 h at 4°C. Endogenous TAPBPR and tapasin were pulled down from the supernatants by using beads coated with either PeTe4 or Pasta-1 antibody, respectively, at 5 μg antibody/sample. After immunoprecipitation, beads were washed thoroughly in 0.1% detergent-TBS to remove unbound protein. The separation by gel electrophoresis was performed as previously described ([@bib12]). Samples were then were transferred onto an Immobilon transfer membrane (Merck Millipore) and analyzed by western blotting as previously described ([@bib20]).

Quantification and Statistical Analysis {#sec4.5}
---------------------------------------

Quantification of protein or peptide binding at the cell surface, measured by flow cytometry was performed using the FlowJo analysis software, version 10. Statistical analysis was performed using GraphPad Prism. Statistical tests and significant values are included in the figure legends.

Data and Code Availability {#sec4.6}
--------------------------

This study did not generate any unique datasets or code.
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